Factors associated with the recurrence of choroidal neovascularization in pathologic myopia.
OCT-angiography
choroidal neovascularization
optical coherence tomography
pathologic myopia
recurrence
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
06
2022
accepted:
24
08
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
30
9
2022
Statut:
epublish
Résumé
To investigate the factors associated with the recurrence of pathologic myopia choroidal neovascularization (PM-CNV). Forty-eight eyes of 48 patients with PM-CNV treated with conbercept at least 6 months of follow-up were included. Appearance of ellipsoid zone (EZ) and retinal pigment epithelium (RPE) observed on optical coherence tomography (OCT). Hyperreflective foci (HRF) height measured on OCT. Observation of CNV shape on OCT-angiography (OCTA). PM-CNV area measured on OCTA. To observe relationship between these factors and best corrected visual acuity (BCVA) and PM-CNV recurrence. The 48 patients (48 eyes) with PM-CNV were divided into two groups: yielding a group of 20 eyes with type 1 and a group of 28 eyes with type 2. The BCVA of type 1 was better than type 2 before and after treatment ( PM-CNV had a higher recurrence ratio. Baseline BCVA and clinical features play an important role for vision prognosis. Factors associated with PM-CNV recurrence include HRF height, CNV area, and changes in EZ and RPE structure.
Identifiants
pubmed: 36172539
doi: 10.3389/fmed.2022.968800
pmc: PMC9510607
doi:
Types de publication
Journal Article
Langues
eng
Pagination
968800Informations de copyright
Copyright © 2022 Jing, Bo, Gao and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eye (Lond). 2019 Aug;33(8):1280-1289
pubmed: 30932032
Drug Des Devel Ther. 2015 Apr 22;9:2311-20
pubmed: 25960634
Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1713-1720
pubmed: 28667483
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1714-1723
pubmed: 31013344
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):45
pubmed: 32343783
Ophthalmology. 2013 May;120(5):1046-56
pubmed: 23352196
Int Ophthalmol. 2017 Aug;37(4):801-806
pubmed: 27591785
Sci Rep. 2020 Oct 12;10(1):16959
pubmed: 33046787
Am J Ophthalmol. 2022 Mar;235:80-89
pubmed: 34509431
Am J Ophthalmol. 2022 Jan;233:18-29
pubmed: 34298010
Br J Ophthalmol. 2017 May;101(5):609-615
pubmed: 27531357
Ophthalmic Res. 2021;64(3):476-482
pubmed: 33221809
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Ophthalmology. 2009 May;116(5):914-20
pubmed: 19410950
Ophthalmology. 2017 Nov;124(11):1690-1711
pubmed: 28655539
Retina. 2020 Sep;40(9):1757-1764
pubmed: 31652198
Ophthalmology. 2011 Apr;118(4):687-93
pubmed: 21093923
Retina. 2015 Nov;35(11):2163-80
pubmed: 26428607
Retina. 2015 May;35(5):999-1006
pubmed: 25590857
J Diabetes Res. 2013;2013:491835
pubmed: 24386645
Br J Ophthalmol. 2019 Jun;103(6):855-862
pubmed: 30636210
Ophthalmol Retina. 2022 Feb;6(2):109-115
pubmed: 33991711
Retina. 2017 Oct;37(10):1931-1941
pubmed: 28033235
Ophthalmology. 2013 May;120(5):1038-45
pubmed: 23352193
Am J Ophthalmol. 2017 May;177:116-125
pubmed: 28237411
Prog Retin Eye Res. 2018 Mar;63:92-106
pubmed: 29111299
Eur J Ophthalmol. 2022 Jan;32(1):15-16
pubmed: 34132138
Ophthalmology. 2020 Sep;127(9):1201-1210
pubmed: 32402554
Int J Ophthalmol. 2021 Aug 18;14(8):1205-1212
pubmed: 34414085
Am J Ophthalmol. 2015 May;159(5):877-83.e7
pubmed: 25634530